Meeting Banner
Abstract #1281

Value of Contrast-Enhanced MRA of the Peripheral Arteries at 3T: Results of a Large European Multicenter Trial Comparing Gadoterate Meglumine-MRA to Gadobutrol-MRA with DSA

Michael Lell1, Javier Arnaiz2, Denis Krause3, Luis Marti-Bonmati4, Manuela Aschauer5, Armando Tartaro6, Massimo Lombardi7, Marta Burrel8, Reynald Izzillo9, Christian Loewe10

1Radiology Department, University-Hospital, Erlangen, Germany; 2University Hospital Marqus de Valdecilla, Santander, Spain; 3Dpartement de Radiologie et d'Imagerie Mdicale Diagnostique et Thrapeutique, CHU Le Bocage, Dijon, France, Metropolitan; 4Dr Peset Hospital, Valencia, Spain; 5Radiology, Universittsklinikum fr Radiologie, Graz, Austria; 6University Gabriel d'Annuzio of Chieti-Pescara, Chieti, Italy; 7Clinical Physiology Institute CNR National Research Council, Pisa, Italy; 8Hospital Clinico, Barcelona, Spain; 9Radiology, Centre Cardiologique du Nord, Saint Denis, France; 10Radiology, AKH Wien - Medizinische Universitt Wien, Vienna, Austria

To date, no prospective randomized trial comparing peripheral CE-MRA at 3T to the reference standard DSA has been performed so far including a large patient population. This multicentre trial including 189 patients was primarily aimed to compare the degrees of agreement in stenosis detection between contrast enhanced-MRA and DSA using two different contrast agents (gadoterate meglumine (Dotarem) or gadobutrol (Gadovist)) inpatients with peripheral arterial occlusive disease (PAOD). This study demonstrates the value of peripheral MRA at 3T for diagnosis and treatment planning in patients suffering from PAOD without any difference between gadoterate meglumine-MRA and gadobutrol-MRA.